This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Gantenerumab

Roche Holding AG

Drug Names(s): R1450, RG1450, RO4909832

Description: R1450 is a monoclonal antibody that targets amyloid beta, a peptide that builds up and aggregates in Alzheimer's disease. Amyloid beta is thought to be involved in the nerve damage seen in the condition.

Deal Structure: Roche and MorphoSys
In September 2000, Roche and MorphoSys announced the signing of an agreement under which the companies will collaborate on the development of human therapeutic antibodies to a biological target of Roche, associated with Alzheimer's disease. Under the terms of the agreement, MorphoSys will receive an upfront payment, development-related milestone payments and royalties on end products. Further financial details were not disclosed. MorphoSys will apply its Human Combinatorial Antibody Library (HuCAL) Fab technology to the generation and optimisation of antibodies to the Roche biological target. Roche will be responsible for the clinical development, regulatory approval and worldwide marketing of any resulting products.

Partners: MorphoSys AG Chugai Pharmaceutical Co., Ltd.


Gantenerumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug